Compare IMMR & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMR | NYXH |
|---|---|---|
| Founded | 1993 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.4M | 188.1M |
| IPO Year | 1999 | 2021 |
| Metric | IMMR | NYXH |
|---|---|---|
| Price | $6.44 | $4.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $12.25 | ★ $12.67 |
| AVG Volume (30 Days) | ★ 689.7K | 41.8K |
| Earning Date | 12-19-2025 | 11-13-2025 |
| Dividend Yield | ★ 4.65% | N/A |
| EPS Growth | ★ 57.07 | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $163,133,000.00 | $6,616,215.00 |
| Revenue This Year | $988.71 | $79.25 |
| Revenue Next Year | $109.72 | $297.08 |
| P/E Ratio | $3.16 | ★ N/A |
| Revenue Growth | ★ 338.21 | 10.96 |
| 52 Week Low | $5.65 | $4.35 |
| 52 Week High | $9.37 | $11.87 |
| Indicator | IMMR | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 42.03 | 48.89 |
| Support Level | $6.42 | $4.69 |
| Resistance Level | $7.09 | $4.93 |
| Average True Range (ATR) | 0.19 | 0.18 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 6.16 | 56.82 |
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.